Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Futibatinib in Patients With Specific FGFR Aberrations
NCT04189445 · Taiho Oncology, Inc. · PHASE2 · terminated · last registry update 2025-10-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor made a strategic decision to terminate the study considering enrollment challenges for some of the cohorts in the trial.” | – | Registry record, Taiho Oncology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-02Results posted on the registry: Memorial Sloan Kettering Cancer Center, BGJ398 (NCT02657486)
- 2026-08-31Results posted on the registry: University of Texas Southwestern Medical Center, a drug against FGFR3 (NCT02956798)
- 2026-08-19Also stopped (terminated): Boundless Bio, Inc., BBI-355 + Erlotinib (NCT05827614)
- 2026-08-13Results posted on the registry: PureTech, Nintedanib 150 MG [Ofev] (NCT06717100)
- 2026-08-11Results posted on the registry: Incyte Corporation, Pemigatinib + Gemcitabine (NCT03656536)
- 2026-08-11Also stopped (terminated): Incyte Corporation, Pemigatinib + Gemcitabine (NCT03656536)
- 2026-08-04Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib + Capecitabine (NCT07745296)
- 2026-07-17Phase 3 first posted: Taiho Pharmaceutical Co., Ltd., Futibatinib + Zimberelimab (NCT07710885)
- 2026-07-09Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Paclitaxel or Docetaxel and Carboplatin or Cisplatin (NCT02009449)
- 2026-06-01Results posted on the registry: Allarity Therapeutics, 2X-121 600 mg + 2X-121 800 mg (NCT05571969)
- 2026-06-01Also stopped (terminated): Allarity Therapeutics, 2X-121 600 mg + 2X-121 800 mg (NCT05571969)
- 2026-05-06Also stopped (suspended): AB Science, Placebo + Masitinib (4.5) (NCT05441488)
- 2026-04-30Results posted on the registry: Icahn School of Medicine at Mount Sinai, Nintedanib + Placebo (NCT04619680)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-04-14Also stopped (terminated): Institut Claudius Regaud, Pazopanib (NCT01642017)
- 2026-04-09Phase 3 first posted: Haisco Pharmaceutical Group Co., Ltd., HSK44459 + HSK44459 (NCT07519070)
- 2026-04-08Results posted on the registry: National Cancer Institute (NCI), Olaparib + Pazopanib (NCT05432791)
- 2026-03-27Also stopped (terminated): M.D. Anderson Cancer Center, Futibatinib + Pembrolizumab (NCT05036681)
- 2026-03-04Results posted on the registry: Boehringer Ingelheim, Nintedanib (Ofev®) (NCT05285982)
- 2026-02-12Also stopped (terminated): Jennifer Lee Caswell-Jin, Infigratinib + Tamoxifen (NCT04504331)
- 2026-02-06Also stopped (terminated): M.D. Anderson Cancer Center, Erdafitinib (NCT04754425)
- 2026-01-13Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986353 + Fludarabine (NCT07335562)
- 2026-01-13Also stopped (terminated): Novartis Pharmaceuticals, LTP001 + Placebo (NCT05497284)
- 2025-12-31Results posted on the registry: Taiho Oncology, Inc., Futibatinib + Pembrolizumab (NCT04601857)
- 2025-12-31Also stopped (terminated): Taiho Oncology, Inc., Futibatinib + Pembrolizumab (NCT04601857)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision